Shah Puja M, Edwards Brandy L, Dietch Zachary C, Guidry Christopher A, Davies Stephen W, Hennessy Sara A, Duane Therese M, O'Neill Patrick J, Coimbra Raul, Cook Charles H, Askari Reza, Popovsky Kimberly, Sawyer Robert G
1 Department of Surgery, University of Virginia , Charlottesville, Virginia.
2 Department of Surgery, John Peter Smith Health Network , Fort Worth, Texas.
Surg Infect (Larchmt). 2016 Feb;17(1):27-31. doi: 10.1089/sur.2015.127. Epub 2015 Sep 23.
Numerous studies have demonstrated microorganism interaction through signaling molecules, some of which are recognized by other bacterial species. This interspecies synergy can prove detrimental to the human host in polymicrobial infections. We hypothesized that polymicrobial intra-abdominal infections (IAI) have worse outcomes than monomicrobial infections.
Data from the Study to Optimize Peritoneal Infection Therapy (STOP-IT), a prospective, multicenter, randomized controlled trial, were reviewed for all occurrences of IAI having culture results available. Patients in STOP-IT had been randomized to receive four days of antibiotics vs. antibiotics until two days after clinical symptom resolution. Patients with polymicrobial and monomicrobial infections were compared by univariable analysis using the Wilcoxon rank sum, χ(2), and Fisher exact tests.
Culture results were available for 336 of 518 patients (65%). The durations of antibiotic therapy in polymicrobial (n = 225) and monomicrobial IAI (n = 111) were equal (p = 0.78). Univariable analysis demonstrated similar demographics in the two populations. The 37 patients (11%) with inflammatory bowel disease were more likely to have polymicrobial IAI (p = 0.05). Polymicrobial infections were not associated with a higher risk of surgical site infection, recurrent IAI, or death.
Contrary to our hypothesis, polymicrobial IAI do not have worse outcomes than monomicrobial infections. These results suggest polymicrobial IAI can be treated the same as monomicrobial IAI.
众多研究已证明微生物通过信号分子相互作用,其中一些信号分子可被其他细菌种类识别。这种种间协同作用在混合微生物感染中可能对人类宿主有害。我们假设混合微生物腹腔内感染(IAI)的预后比单一微生物感染更差。
对优化腹膜感染治疗研究(STOP-IT)的数据进行回顾,该研究是一项前瞻性、多中心、随机对照试验,纳入了所有有可用培养结果的IAI病例。STOP-IT研究中的患者被随机分为接受四天抗生素治疗组与临床症状缓解后两天继续使用抗生素组。使用Wilcoxon秩和检验、χ²检验和Fisher精确检验对混合微生物感染和单一微生物感染的患者进行单变量分析比较。
518例患者中有336例(65%)有可用培养结果。混合微生物感染(n = 225)和单一微生物IAI(n = 111)的抗生素治疗持续时间相等(p = 0.78)。单变量分析显示两组患者的人口统计学特征相似。37例(11%)炎症性肠病患者更易发生混合微生物IAI(p = 0.05)。混合微生物感染与手术部位感染、复发性IAI或死亡的较高风险无关。
与我们的假设相反,混合微生物IAI的预后并不比单一微生物感染更差。这些结果表明,混合微生物IAI与单一微生物IAI的治疗方式相同。